The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.
暂无分享,去创建一个
[1] S. Rosenberg,et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Allison,et al. Checkpoint blockade in cancer immunotherapy. , 2007, Advances in immunology.
[3] S. Rosenberg,et al. Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study , 2005, Annals of Surgical Oncology.
[4] S. O’Day,et al. The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma , 2007 .
[5] Thomas A. Davis,et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[6] J. Bluestone,et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.
[7] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[8] M. Morse. Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb. , 2005, Current opinion in molecular therapeutics.
[9] A. Pavlick,et al. DURABLE RESPONSES AND LONG-TERM PROGRESSION- FREE SURVIVAL OBSERVED IN A PHASE II STUDY OF MDX- 010 ALONE OR IN COMBINATION WITH DACARBAZINE (DTIC) IN METASTATIC MELANOMA. , 2005 .
[10] H. Griesser,et al. Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.
[11] A. Korman,et al. MDX-010 (human anti-CTLA4): a phase I trial in malignant melanoma , 2002 .